KI-67抗體市場規模、佔有率和成長分析：按產品類型、應用、最終用戶、宿主類型、克隆性別、分銷管道和地區分類 - 行業預測，2026-2033年

2024 年全球 KI-67 抗體市值為 2.847 億美元，預計到 2025 年將成長至 3.0861 億美元，到 2033 年將成長至 5.8838 億美元，在預測期（2026-2033 年）內複合年成長率為 8.4%。

全球KI-67抗體市場的主要驅動力是腫瘤診斷中對精準增殖生物標記日益成長的需求。 KI-67對於評估腫瘤侵襲性、制定治療策略以及在臨床試驗中進行隊列分層至關重要。隨著KI-67評分被納入癌症治療指南，其市場重要性進一步提升。對高精度KI-67檢測的需求持續成長，尤其是在標靶治療和免疫查核點抑制劑興起之後，越來越多的臨床醫生在製定治療策略時依賴定量生物標記數據。此外，人工智慧驅動的數位病理學正在改變市場格局，推動影像分析和評分的自動化程度提高，增強了結果的一致性，並簡化了大規模檢查室工作量的管理。對數位病理學投資的激增正在提升對經驗檢驗的KI-67抗體的需求，並推動抗體研發的創新。

全球KI-67抗體市場促進因素

隨著精準腫瘤學研究的日益普及，Ki-67抗體檢測的應用也日益廣泛，醫療專業人員正尋求可靠的標記物來評估腫瘤侵襲性並制定個人化治療策略。這一趨勢正在推動全球研究機構和診斷檢查室對這些試劑的應用，從而持續刺激對高品質產品的需求，並促進創新檢測方法的研發。越來越多的臨床證據表明Ki-67具有預後標誌物的作用，這推動了其在標準病理實踐中的應用，促進了檢查室能力建設和供應商分銷網路的拓展。這些因素共同推動了市場成長，並促進了持續的研究夥伴關係。

全球KI-67抗體市場的限制因素

由於高成本高昂，這成為其廣泛應用的主要障礙，尤其是在開發中地區預算緊張的檢查室中。由於資金限制在採購決策中起著決定性作用，許多機構可能會選擇更經濟實惠的替代標誌物，或推遲引入該檢測。這導致整體需求下降，阻礙了市場成長。這種經濟負擔往往導致人們優先考慮必要的診斷工具而非專用試劑，進一步阻礙了KI-67抗體的廣泛應用，儘管其具有重要的臨床意義，也阻礙了小規模研究機構投資於先進的診斷技術。

全球KI-67抗體市場趨勢

全球KI-67抗體市場正呈現出對個人化癌症診斷顯著發展的趨勢，這主要得益於精準醫療的日益普及。實驗室擴大採用KI-67抗體來最佳化治療方案、評估治療反應並根據腫瘤侵襲性對患者進行分類。這種模式轉移要求製造商不斷創新，生產出高度特異性和可重複性的抗體克隆。此外，不斷增強的技術支援促進了與醫療服務提供者的合作，最終推動市場拓展至傳統病理檢查室之外。因此，全球分銷管道和培訓計畫也在不斷擴展，KI-67抗體正逐漸成為個人化癌症治療策略中的關鍵工具。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球KI-67抗體市場規模：依產品類型分類

• 單株抗體
• 多株抗體
• 重組抗體
• 其他

全球KI-67抗體市場規模：依應用領域分類

• 免疫組織化學
• 蛋白質印跡法
• 流式細胞技術
• 其他

全球KI-67抗體市場規模：依最終用戶分類

• 學術研究機構
• 製藥和生物技術公司
• 臨床實驗室
• 其他

全球KI-67抗體市場規模：依宿主類型分類

• 兔子
• 老鼠
• 其他

全球KI-67抗體市場規模：克隆性別

• 單株抗體
• 多克隆抗體

全球KI-67抗體市場規模：依分銷管道分類

• 直銷
• 檢測試劑經銷商
• 其他

全球KI-67抗體市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Abcam plc
• Cell Signaling Technology, Inc.
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• Bio-Techne Corporation
• Santa Cruz Biotechnology, Inc.
• GeneTex, Inc.
• Proteintech Group, Inc.
• Novus Biologicals LLC
• OriGene Technologies, Inc.
• Creative Diagnostics
• Atlas Antibodies AB
• Rockland Immunochemicals, Inc.
• GenScript Biotech Corporation
• Boster Biological Technology
• BioLegend, Inc.
• Miltenyi Biotec BV & Co. KG
• RayBiotech Life, Inc.
• Cusabio Technology LLC

結論與建議

Global Ki-67 Antibody Market size was valued at USD 284.7 Million in 2024 and is poised to grow from USD 308.61 Million in 2025 to USD 588.38 Million by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The global Ki-67 antibody market is primarily driven by the increasing need for accurate proliferative biomarkers in oncology diagnostics. Ki-67 is vital for evaluating tumor aggression, directing therapy, and cohort stratification in clinical trials. The integration of Ki-67 scoring into cancer treatment guidelines has heightened its market significance. As more clinicians rely on quantitative biomarker data for treatment decisions, especially with the rise of targeted therapies and immune checkpoint inhibitors, the demand for precise Ki-67 assays continues to grow. Moreover, the influence of AI-driven digital pathology is transforming the landscape by automating image analysis and scoring, enhancing consistency, and facilitating larger workload management in labs. This surge in digital pathology investments boosts demand for validated Ki-67 antibodies and encourages innovation in antibody development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ki-67 Antibody market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ki-67 Antibody Market Segments Analysis

Global ki-67 antibody market is segmented by product type, application, end user, host species, clonality, distribution channel and region. Based on product type, the market is segmented into Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies and Others. Based on application, the market is segmented into Immunohistochemistry, Western Blotting, Flow Cytometry and Others. Based on end user, the market is segmented into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical Laboratories and Others. Based on host species, the market is segmented into Rabbit, Mouse and Others. Based on clonality, the market is segmented into Monoclonal and Polyclonal. Based on distribution channel, the market is segmented into Direct Sales, Laboratory Distributors and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ki-67 Antibody Market

The rising focus on precision oncology is propelling the widespread usage of Ki-67 antibody assays as healthcare professionals look for dependable markers to assess tumor aggressiveness and inform tailored treatment strategies. This trend enhances the applicability of these reagents in research and diagnostic labs globally, driving sustained demand for high-quality products and encouraging investment in the development of innovative assays. Increasing clinical evidence that highlights Ki-67's role as a prognostic marker supports its incorporation into standard pathology practices, motivating laboratories to enhance their capabilities and suppliers to expand their distribution networks, which collectively strengthens market growth and promotes ongoing research partnerships.

Restraints in the Global Ki-67 Antibody Market

The high costs associated with high-purity Ki-67 antibodies, due to intensive purification methods and rigorous quality standards, pose significant barriers to their widespread adoption, especially in budget-restricted laboratories found in developing regions. As financial limitations play a crucial role in procurement choices, many institutions may choose to utilize more affordable alternative markers or postpone the implementation of assays, ultimately diminishing overall demand and hindering market growth. This financial strain often leads to a preference for essential diagnostic tools over specialized reagents, further obstructing the wider acceptance of Ki-67 antibodies despite their clinical importance, and deterring smaller research entities from investing in advanced diagnostic technologies.

Market Trends of the Global Ki-67 Antibody Market

The Global Ki-67 Antibody market is witnessing a significant trend towards personalized oncology diagnostics, driven by the increasing focus on precision medicine. Laboratories are increasingly incorporating Ki-67 antibodies to refine treatment protocols, evaluate therapeutic responses, and categorize patients according to tumor aggressiveness. This paradigm shift compels manufacturers to innovate and produce highly specific, reproducible antibody clones. Furthermore, it promotes collaboration with healthcare providers through enhanced technical support, ultimately broadening market reach beyond traditional pathology labs. As a result, global distribution channels and training initiatives are expanding, positioning Ki-67 antibodies as pivotal tools in personalized cancer care strategies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global KI-67 Antibody Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Antibodies
• Others

Global KI-67 Antibody Market Size by Application & CAGR (2026-2033)

• Market Overview
• Immunohistochemistry
• Western Blotting
• Flow Cytometry
• Others

Global KI-67 Antibody Market Size by End User & CAGR (2026-2033)

• Market Overview
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Clinical Laboratories
• Others

Global KI-67 Antibody Market Size by Host Species & CAGR (2026-2033)

• Market Overview
• Rabbit
• Mouse
• Others

Global KI-67 Antibody Market Size by Clonality & CAGR (2026-2033)

• Market Overview
• Monoclonal
• Polyclonal

Global KI-67 Antibody Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Laboratory Distributors
• Others

Global KI-67 Antibody Market Size & CAGR (2026-2033)

• North America (Product Type, Application, End User, Host Species, Clonality, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Application, End User, Host Species, Clonality, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, End User, Host Species, Clonality, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, End User, Host Species, Clonality, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, End User, Host Species, Clonality, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Abcam plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Signaling Technology, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santa Cruz Biotechnology, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneTex, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proteintech Group, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novus Biologicals LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OriGene Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atlas Antibodies AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rockland Immunochemicals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boster Biological Technology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioLegend, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Miltenyi Biotec B.V. & Co. KG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RayBiotech Life, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cusabio Technology LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations